R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

Take the hybrid road to bring clinical trials to patients

As the landscape of clinical trials evolves, decentralised clinical trials (DCTs) have emerged to put patients at the centre of the research process.

R&D

Pharma waste management: Balancing cost, compliance, and env...

In an era where healthcare advancements are at their peak, an often overlooked, yet critical, aspect is the management of pharmaceutical waste.

R&D

JP Morgan 2024 – Graham Heap

Just over a year ago, Takeda acquired a promising immunotherapy candidate, TAK-279, from Boston-based Nimbus Therapeutics.

R&D

Abstract laptop with coloured DNA molecule

Understanding the impact of AI on the advancement of gene th...

The biopharmaceutical landscape stands at the cusp of a transformative era, with artificial intelligence (AI) leading the charge.

R&D

Why Scotland is well-positioned to lead in advanced therapie...

The global health burden of complex diseases such as severe lung, liver, and vascular disease is huge, and growing by the second.

R&D

This week in clinical trials: 8th-12th January

In our second clinical trials update of 2024, taking in developments in life sciences research and development from early-stage onwards, we look at a wide range of announcements – from onco